Moberg Pharma AB (publ) (MB8.F)
- Previous Close
2.5300 - Open
3.0240 - Bid 2.9120 x --
- Ask 3.0140 x --
- Day's Range
3.0240 - 3.0920 - 52 Week Range
0.3260 - 3.2320 - Volume
950 - Avg. Volume
1,068 - Market Cap (intraday)
109.009M - Beta (5Y Monthly) 1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
--
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. The company develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
www.mobergpharma.se10
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MB8.F
Performance Overview: MB8.F
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MB8.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MB8.F
Valuation Measures
Market Cap
85.75M
Enterprise Value
81.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.34
Enterprise Value/Revenue
75.71
Enterprise Value/EBITDA
-3.51
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-2.91%
Return on Equity (ttm)
-3.69%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.09M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
60.55M
Total Debt/Equity (mrq)
0.78%
Levered Free Cash Flow (ttm)
-149.44M
Company Insights: MB8.F
MB8.F does not have Company Insights